A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind)

Trial Profile

A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Propranolol (Primary)
  • Indications Haemangioma
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 24 Feb 2015 New trial record
    • 20 Feb 2015 According to a Pierre Fabre media release, the results of this trial were presented in New England Journal of Medicine.
    • 20 Feb 2015 Results published in a Pierre Fabre media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top